Trials / Completed
CompletedNCT02612922
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 325 (actual)
- Sponsor
- Romark Laboratories L.C. · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.
Detailed description
A multicenter randomized double-blind placebo controlled trial designed to evaluate efficacy and safety of NTZ 600 mg administered orally twice daily for five days compared to a placebo in the treatment of acute uncomplicated influenza.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitazoxanide | Nitazoxanide 600 mg administered orally twice daily for five days |
| DRUG | Placebo | Placebo administered orally twice daily for five days |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-09-04
- Completion
- 2016-09-04
- First posted
- 2015-11-24
- Last updated
- 2018-04-04
Locations
28 sites across 3 countries: United States, Australia, Puerto Rico
Source: ClinicalTrials.gov record NCT02612922. Inclusion in this directory is not an endorsement.